The Company is a Singapore-based biopharmaceutical company. The Company is focused on the development of biosimilars and antibody drugs as well as vaccines for infectious diseases. The Company s biosimilar portfolio includes Herceptin Biosimilar (HD201), Avastin Biosimilar (HD204), and Humira Biosimilar (PBP1502). Its antibody therapeutics portfolio includes PBP1510 Anti-PAUF antibody for pancreatic cancer and PBP1710 Anti-CTHRC1 antibody for solid tumors. Its products in line include a Bevacizumab biosimilar (HD204) in Phase III, an Adalimumab biosimilar (PBP1502) in Phase I, and an anti-PAUF mAb (PBP1510) for the treatment of pancreatic cancer in Phase I stages. Its IDC001 is designed to treat cancers that express relatively high levels of PAUF and CTHRC1. The Company s manufacturing facilities for global commercial supply are located in Osong, South Korea.
Headquarters
21 Biopolis Road, 04-24/28 Nucleos South Building
Singapore; Singapore;
Contact Details: Purchase the Prestige Biopharma report to view the information.
Website: http://www.prestigebiopharma.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service